/

SPRB

Spruce Biosciences, Inc.Closed

40.35−2.52 −5.88%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delay

Open

42.80

Prev close

42.87

Day range

40.1942.91

52-week range

40.19188.25

Volume

110.57K1.42×

Mkt cap

115.97M

P/E ttm

—

Fwd P/E

8.11

EPS ttm

-39.12

Div yield

0.00%

Earnings

—

From 52w high

−78.57%

Price Chart

Yahoo Finance · delayed

SPRBOct 13, 2026O 42.80H 42.91L 40.19C 40.35−2.52 (−5.88%)Vol 110.60K

SMA 5051.48
SMA 20058.25

1Y change −74.62% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

SPRB Spruce Biosciences, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −5.69%
1 month: −24.86%
3 months: −12.96%
6 months: −40.49%
Year to date: −53.68%
1 year: −74.62%

Valuation & ownership

Market cap: 115.97M
Enterprise value: 27.34M
P/E (ttm): —
Forward P/E: 8.11
PEG ratio: —
Price / book: 1.33
Price / sales (ttm): —
EV / EBITDA: -0.70
EPS (ttm): -39.12
EPS (forward): 4.98
Beta (5y monthly): 3.30
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 2.87M
Float: 2.02M
Short % of float: 15.17%
Short ratio (days): 4.02
Held by insiders: 3.37%
Held by institutions: 76.88%
Avg volume (3m): 77.63K
50-day average: 51.54
200-day average: 58.47
52-week change: −74.62%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 30.7
vs 50-day SMA: −21.62%
vs 200-day SMA: −30.73%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 7.63%
Realised vol (20d, ann.): 52.6%
From 52-week high: −78.57%
From 52-week low: +0.40%

ANR

Analyst Consensus

9 analysts

Consensus

Strong buy

1.11 on a 1 (strong buy) – 5 (sell) scale

Mean target

148.00

+266.79% implied

Low 104.00Median 144.00High 230.00

Recommendation trend

Now9 / 0 / 0
1m ago9 / 0 / 0

DES

About Spruce Biosciences, Inc.

Yahoo Finance profile

Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and somatic changes, including anhedonia, weight alterations, and altered sleeping patterns. In addition, the company develops SPR202 for the treatment of Congenital Adrenal Hyperplasia (CAH), a chronic and potentially life-threatening rare disease with no cure. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize various pharmaceutical compounds. It also has a collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize Tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.

Sector: Healthcare
Industry: Biotechnology
Employees: 22
Headquarters: South San Francisco, CA, United States
Website: sprucebio.com
Officers: Mr. Michael G. Grey Executive Chairman
Dr. Javier Szwarcberg M.D., M.P.H. CEO & Director

SEAS

Seasonality · SPRB

2020–2026 · monthly returns

Strongest month Oct +210.52%Weakest month Mar −28.88%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-11.0	-29.2	18.9	-12.3	-10.6	5.3	-20.7	37.7	-17.6	-16.9			−53.7%
2025	-10.7	3.7	-25.4	-72.8	-17.7	12.3	50.7	-98.9	27.9	1130.2	-9.2	-12.9	−96.3%
2024	24.9	36.6	-84.3	-9.9	4.7	-30.1	-0.2	-10.1	2.2	11.8	3.0	-23.2	−85.7%
2023	168.9	-23.1	-2.6	-6.8	18.0	-11.5	4.7	0.0	0.4	-49.6	22.8	109.3	+167.1%
2022	-43.0	-10.6	-11.5	-12.4	-11.4	11.5	6.3	18.4	-37.4	-19.0	-0.9	-0.3	−75.4%
2021	-14.7	0.8	-20.6	-2.4	-12.8	-20.7	-17.8	-16.7	-21.6	-20.8	-45.8	72.9	−81.7%
2020											30.9	-15.1	+11.1%

INSD

Insider Activity · SPRB

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Jun 29, 2026	Szwarcberg Javier B M.D.Chief Executive Officer	Stock Award(Grant) at price 54.00 per share.	266	$14.36K
Dec 30, 2025	Szwarcberg Javier B M.D.Chief Executive Officer	Stock Award(Grant) at price 87.11 per share.	4.7K	$408.55K
Dec 14, 2025	Gharib Samir MPresident	—	1K	—
Dec 14, 2025	Szwarcberg Javier B M.D.Chief Executive Officer	—	2.7K	—
Dec 10, 2025	Gharib Samir MPresident	—	2.4K	—
Dec 10, 2025	Ways Douglas Kirk M.D., Ph.D.Officer and Director	—	1.3K	—
Dec 10, 2025	Szwarcberg Javier B M.D.Chief Executive Officer	—	6.1K	—
Oct 19, 2025	Gharib Samir MPresident	—	2.1K	—
Oct 19, 2025	Szwarcberg Javier B M.D.Chief Executive Officer	—	4.8K	—
Oct 5, 2025	Parkman Healthcare Partners LlcBeneficial Owner of more than 10% of a Class of Security	Sale at price 130.40 per share.	257	$33.51K
Oct 5, 2025	Parkman Healthcare Partners LlcBeneficial Owner of more than 10% of a Class of Security	Sale at price 130.40 per share.	257	$33.51K
Oct 5, 2025	Parkman Healthcare Partners LlcBeneficial Owner of more than 10% of a Class of Security	Purchase at price 130.40 per share.	256	$33.38K
Oct 5, 2025	Parkman Healthcare Partners LlcBeneficial Owner of more than 10% of a Class of Security	Purchase at price 130.40 per share.	256	$33.38K
Dec 15, 2024	Gharib Samir MPresident	—	229.8K	—
Dec 15, 2024	Szwarcberg Javier B M.D.Chief Executive Officer	—	559.5K	—
Dec 15, 2024	Charlton Ralph William IiiOfficer	—	164.8K	—

13F

Investors Holding SPRB

latest 13F filings of 29 followed managers

Investors holding SPRB
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$253.8K	0.00%	4.70K	New	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

SPRB

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

SPRB

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Spruce Biosciences, Inc.

Seasonality · SPRB

Insider Activity · SPRB

Congress Trades · SPRB

Investors Holding SPRB

Investors Holding SPRB

Congress Trades · SPRB

Insider Activity · SPRB

Seasonality · SPRB

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Spruce Biosciences, Inc.

Financial Snapshot

Earnings & Dividends

News